Latest Breaking News On - Bio therapeutics - Page 4 : vimarsana.com

Syncona : SwanBio Evolves Leadership Team with Appointment of Executive Chair and Chief Operating Officer -October 16, 2023 at 06:41 am EDT

SwanBio Therapeutics, a gene therapy company developing AAV-based therapies for the treatment of devastating, inherited neurological conditions, today announced the addition of two industry.

Aytu biopharmaJohn tsaiChris hollowoodLara furstSyncona swanbioTom andersonEuropean medicines agencySyncona ltdDrug administrationSyncona investment managementSwanbio therapeuticsTopher brookeSyncona investment management limitedForcefield therapeuticsRumpus therapeuticsBio therapeutics

SwanBio Evolves Leadership Team with Appointment of Executive Chair and Chief Operating Officer

PHILADELPHIA (BUSINESS WIRE) Oct 16, 2023

Chris hollowoodAytu biopharmaTom andersonJohn tsaiLara furstDrug administrationSyncona ltdSyncona investment managementEuropean medicines agencyBio therapeuticsTopher brookeSyncona investment management limitedForcefield therapeuticsRumpus therapeuticsFast trackOrphan drug designation

SwanBio Therapeutics: SwanBio Advances to Higher-Dose Cohort in First-in-Human Study of Gene Therapy for Adrenomyeloneuropathy

SwanBio Therapeutics: SwanBio Advances to Higher-Dose Cohort in First-in-Human Study of Gene Therapy for Adrenomyeloneuropathy
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomChris hollowoodLara furstDavid weinerCentral committee on research involving human subjectsSyncona investment managementSyncona ltdDrug administrationEuropean medicines agencyBio therapeuticsData safety monitoring boardSyncona investment management limitedClinical trial applicationCentral committeeResearch involving human subjects

SwanBio Advances to Higher-Dose Cohort in First-in-Human Study of Gene Therapy for Adrenomyeloneuropathy

PHILADELPHIA (BUSINESS WIRE) Oct 4, 2023

United statesUnited kingdomDavid weinerLara furstChris hollowoodEuropean medicines agencyCentral committee on research involving human subjectsDrug administrationSyncona ltdSyncona investment managementBio therapeuticsData safety monitoring boardSyncona investment management limitedClinical trial applicationCentral committeeResearch involving human subjects

Syncona : SwanBio Advances to Higher-Dose Cohort in First-in-Human Study of Gene Therapy for Adrenomyeloneuropathy -October 04, 2023 at 07:28 am EDT

Independent Data Safety Monitoring Board recommended dose escalation First patient in cohort 2 has received SBT101 Majority investor Syncona providing new.

United kingdomUnited statesChris hollowoodLara furstDavid weinerEuropean medicines agencyCentral committee on research involving human subjectsDrug administrationSyncona investment managementSyncona ltdIndependent data safety monitoring boardBio therapeuticsData safety monitoring boardClinical trial applicationCentral committeeResearch involving human subjects